University of Maryland sends cease-and-desist to Colorado cannabis company over name, logo
#35 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
The University of Maryland issued a cease-and-desist letter to a Colorado cannabis company over alleged trademark infringement involving the university’s name and logo. This legal action reflects growing tensions between academic institutions and cannabis businesses operating in states where cannabis is legal, as companies may attempt to leverage recognizable institutional branding to enhance product credibility or market appeal. While the specific details of the infringement claim are not fully outlined in this summary, such disputes highlight the broader challenge of protecting institutional intellectual property in an expanding legal cannabis market. From a clinical perspective, this case underscores the importance of distinguishing between cannabis products marketed under legitimate institutional affiliations versus those misappropriating academic names, which could mislead patients about product quality, testing standards, or scientific endorsement. Clinicians should be cautious when patients reference cannabis products claiming university affiliation or endorsement and verify such claims directly with the institution before considering recommendations. Patients and providers should independently verify the legitimacy of cannabis product claims and avoid products that misrepresent institutional backing or scientific validation.
🏫 While this trademark dispute between an academic institution and a cannabis company may seem tangential to clinical care, it reflects the broader challenge clinicians face as cannabis products proliferate in increasingly commercialized markets with varying quality standards and marketing practices. The case underscores how cannabis industry growth has outpaced regulatory infrastructure, leaving healthcare providers with limited reliable information about product identity, potency, and safety—particularly when companies adopt names or logos that might confuse consumers about product origins or legitimacy. Clinicians should remain aware that patients may not always accurately identify which cannabis products they are using, either because they were misled by branding or because they obtained products through informal channels, complicating clinical history-taking and risk assessment. Given these naming and trademark uncertainties in the marketplace, providers should directly ask patients about specific product types, THC/CBD ratios, and source of purchase when taking a cannabis use history, rather than relying on patient recall of
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
